PFIZER Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?
PFIZER has one hundred and ninety-five approved drugs.
There are fifty-one US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and fifty-one patent family members on PFIZER drugs in seventy countries and two hundred and sixty-six supplementary protection certificates in nineteen countries.
Summary for PFIZER
| International Patents: | 1051 |
| US Patents: | 51 |
| Tradenames: | 159 |
| Ingredients: | 130 |
| NDAs: | 195 |
| Drug Master File Entries: | 3 |
| Patent Litigation for PFIZER: | See patent lawsuits for PFIZER |
| PTAB Cases with PFIZER as petitioner: | See PTAB cases with PFIZER as petitioner |
Drugs and US Patents for PFIZER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | SPECTROBID | bacampicillin hydrochloride | TABLET;ORAL | 050520-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-006 | Jun 20, 2023 | RX | Yes | No | 10,780,088 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pfizer | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-003 | Mar 7, 2024 | RX | Yes | No | 8,012,976 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Pfizer | IBRANCE | palbociclib | TABLET;ORAL | 212436-003 | Nov 1, 2019 | AB | RX | Yes | Yes | RE47739 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | 8,481,546 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Pfizer | TROXYCA ER | naltrexone hydrochloride; oxycodone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 207621-002 | Aug 19, 2016 | DISCN | No | No | 7,815,934 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PFIZER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | GLUCOTROL XL | glipizide | TABLET, EXTENDED RELEASE;ORAL | 020329-003 | Aug 10, 1999 | 5,024,843 | ⤷ Subscribe |
| Pfizer | SONATA | zaleplon | CAPSULE;ORAL | 020859-002 | Aug 13, 1999 | 4,626,538 | ⤷ Subscribe |
| Pfizer | TROVAN PRESERVATIVE FREE | alatrofloxacin mesylate | INJECTABLE;INJECTION | 020760-001 | Dec 18, 1997 | 5,763,454 | ⤷ Subscribe |
| Pfizer | DIFLUCAN | fluconazole | FOR SUSPENSION;ORAL | 020090-001 | Dec 23, 1993 | 4,416,682 | ⤷ Subscribe |
| Pfizer | IBRANCE | palbociclib | TABLET;ORAL | 212436-003 | Nov 1, 2019 | 6,936,612 | ⤷ Subscribe |
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | 7,220,862 | ⤷ Subscribe |
| Pfizer | PROCARDIA | nifedipine | CAPSULE;ORAL | 018482-001 | Approved Prior to Jan 1, 1982 | 3,784,684 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
| ➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
| ➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
| ➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
| ➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
International Patents for PFIZER Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| El Salvador | 2016005209 | ⤷ Subscribe |
| Argentina | 123111 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 03104236 | ⤷ Subscribe |
| Portugal | 2488512 | ⤷ Subscribe |
| Israel | 277272 | ⤷ Subscribe |
| Australia | 2011233627 | ⤷ Subscribe |
| Argentina | 104391 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PFIZER Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1666481 | PA2017025 | Lithuania | ⤷ Subscribe | PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322 |
| 1470124 | 1790011-9 | Sweden | ⤷ Subscribe | PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/16/1147 20161111 |
| 0208846 | SPC/GB99/024 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312 |
| 1470124 | 614 | Finland | ⤷ Subscribe | |
| 2767537 | PA2019522 | Lithuania | ⤷ Subscribe | PRODUCT NAME: TALAZOPARIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/19/1377 20190620 |
| 1666481 | 2017/036 | Ireland | ⤷ Subscribe | PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REGISTRATION NO/DATE: EU/1/17/1178/001 EU/1/17/1178/004 20170322 |
| 0413455 | SPC/GB98/045 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: TROVAFLOXACIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE MESYLATE SALT.; REGISTERED: CH 54483 19980327; UK EU/1/98/059/001 19980703; UK EU/1/98/059/002 19980703; UK EU/1/98/059/003 19980703; UK EU/1/98/059/004 19980703; UK EU/1/98/059/005 19980703; UK EU/1/98/059/006 19980703; UK EU/1/98/059/007 19980703; UK EU/1/98/059/008 19980703; UK EU/1/98/059/009 19980703; UK EU/1/98/059/010 19980703; UK EU/1/98/059/011 19980703; UK EU/1/98/059/012 19980703 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
